2025 ICD-10-CM Diagnosis Code C80.1

by

Malignant (primary) neoplasm, unspecified

  • C80.1 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
  • The 2025 edition of ICD-10-CM C80.1 became effective on October 1, 2024.
  • This is the American ICD-10-CM version of C80.1 – other international versions of ICD-10 C80.1 may differ.

Applicable To

  • Cancer NOS
  • Cancer unspecified site (primary)
  • Carcinoma unspecified site (primary)
  • Malignancy unspecified site (primary)

Type 1 Excludes

  • secondary malignant neoplasm of unspecified site (C79.9)

The following code(s) above C80.1 contain annotation back-references

 that may be applicable to C80.1:

  • C00-D49  Neoplasms
  • C80  Malignant neoplasm without specification of site

Approximate Synonyms

  • Adenocarcinoma in adenomatous polyp
  • Adenocarcinoma metastatic to unspecified site
  • Cancer
  • Cancer in childbirth
  • Cancer in pregnancy
  • Cancer metastatic to bone
  • Cancer metastatic to ovary
  • Cancer metastatic to parotid gland
  • Cancer metastatic to vagina
  • Cancer of unknown primary
  • Cancer related fatigue
  • Cancer, adenocarcinoma
  • Cancer, adenocarcinoma in adenomatous polyp
  • Cancer, adenocarcinoma in villous adenoma
  • Cancer, germ cell
  • Cancer, small cell
  • Cancer, undifferentiated large cell
  • Dilated cardiomyopathy secondary to malignancy
  • Dilated cardiomyopathy, due to malignancy
  • Eaton lambert syndrome
  • Eaton lambert syndrome due to cancer
  • Fatigue due to malignant neoplastic disease
  • Malignant adenomatous neoplasm
  • Malignant adenomatous neoplasm in villous adenoma
  • Malignant ascites
  • Malignant neoplasm
  • Malignant neoplastic disease
  • Malignant neoplastic disease in pregnancy
  • Malignant neoplastic disease postpartum
  • Muir torre syndrome w benign sebaceous neoplasm
  • Muir torre syndrome w malignant sebaceous neoplasm
  • Myelopathy due to malignant neoplastic disease
  • Myelopathy in malignant neoplasm
  • Neoplastic pleural effusion
  • Neuropathy (nerve damage), peripheral paraneoplastic
  • Paraneoplastic peripheral neuropathy
  • Pleural effusion due to malignancy
  • Postpartum cancer (after childbirth)
  • Primary malignant germ cell tumor
  • Primary malignant neoplasm
  • Primary malignant neoplasm of unknown site
  • Primary malignant neoplasm of unspecified site (clinical)
  • Primitive neuroectodermal tumor (pnet)
  • Primitive non central nervous system neuroectodermal tumor
  • Restrictive cardiomyopathy secondary to malignancy
  • Restrictive cardiomyopathy, due to malignancy
  • Secondary adenocarcinoma
  • Secondary malignant neoplasm of bone
  • Secondary malignant neoplasm of ovary
  • Secondary malignant neoplasm of parotid gland
  • Secondary malignant neoplasm of vagina
  • Secondary small cell carcinoma of unspecified site
  • Small cell carcinoma
  • Small cell carcinoma metastatic to unspecified site
  • Torr?-muir syndrome with benign sebaceous neoplasm
  • Torr?-muir syndrome with malignant sebaceous neoplasm
  • Torrù-muir syndrome with benign sebaceous neoplasm
  • Undifferentiated large cell primary malignant neoplasm

Clinical Information

  • A general term for autonomous tissue growth exhibiting morphologic features of malignancy (e.g. Severe atypia, nuclear pleomorphism, tumor cell necrosis, abnormal mitoses, tissue invasiveness) and for which the transformed cell type has not been specifically identified.
  • A term for diseases in which abnormal cells divide without control and can invade nearby tissues. Malignant cells can also spread to other parts of the body through the blood and lymph systems. There are several main types of malignancy. Carcinoma is a malignancy that begins in the skin or in tissues that line or cover internal organs. Sarcoma is a malignancy that begins in bone, cartilage, fat, muscle, blood vessels, or other connective or supportive tissue. Leukemia is a malignancy that starts in blood-forming tissue such as the bone marrow, and causes large numbers of abnormal blood cells to be produced and enter the blood. Lymphoma and multiple myeloma are malignancies that begin in the cells of the immune system. Central nervous system cancers are malignancies that begin in the tissues of the brain and spinal cord.
  • A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), hodgkin and non-hodgkin lymphomas, leukemias, melanomas, and sarcomas.
  • Cancer begins in your cells, which are the building blocks of your body. Normally, your body forms new cells as you need them, replacing old cells that die. Sometimes this process goes wrong. New cells grow even when you don’t need them, and old cells don’t die when they should. These extra cells can form a mass called a tumor. Tumors can be benign or malignant. benign tumors aren’t cancer while malignant ones are. Cells from malignant tumors can invade nearby tissues. They can also break away and spread to other parts of the body. Most cancers are named for where they start. For example, lung cancer starts in the lung, and breast cancer starts in the breast. The spread of cancer from one part of the body to another is called metastasis. Symptoms and treatment depend on the cancer type and how advanced it is. Treatment plans may include surgery, radiation and/or chemotherapy. nih: national cancer institute
  • New abnormal tissue that grows by excessive cellular division and proliferation more rapidly than normal and continues to grow after the stimuli that initiated the new growth cease; tumors perform no useful body function and may be benign or malignant; benign neoplasms are a noncancerous growth that does not invade nearby tissue or spread to other parts of the body; malignant neoplasms or cancer show a greater degree of anaplasia and have the properties of invasion and metastasis; neoplasm terms herein do not distinguish between benign or malignant states, use references listed to cover this concept.

ICD-10-CM C80.1 is grouped within Diagnostic Related Group(s) (MS-DRG v42.0):

  • 826 Myeloproliferative disorders or poorly differentiated neoplasms with major o.r. Procedures with mcc
  • 827 Myeloproliferative disorders or poorly differentiated neoplasms with major o.r. Procedures with cc
  • 828 Myeloproliferative disorders or poorly differentiated neoplasms with major o.r. Procedures without cc/mcc
  • 829 Myeloproliferative disorders or poorly differentiated neoplasms with other procedures with cc/mcc
  • 830 Myeloproliferative disorders or poorly differentiated neoplasms with other procedures without cc/mcc
  • 843 Other myeloproliferative disorders or poorly differentiated neoplastic diagnoses with mcc
  • 844 Other myeloproliferative disorders or poorly differentiated neoplastic diagnoses with cc
  • 845 Other myeloproliferative disorders or poorly differentiated neoplastic diagnoses without cc/mcc

Convert C80.1 to ICD-9-CMCode History

  • 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
  • 2017 (effective 10/1/2016): No change
  • 2018 (effective 10/1/2017): No change
  • 2019 (effective 10/1/2018): No change
  • 2020 (effective 10/1/2019): No change
  • 2021 (effective 10/1/2020): No change
  • 2022 (effective 10/1/2021): No change
  • 2023 (effective 10/1/2022): No change
  • 2024 (effective 10/1/2023): No change
  • 2025 (effective 10/1/2024): No change

Code annotations containing back-references to C80.1:

Diagnosis Index entries containing back-references to C80.1:

error: Content is protected !!